Tom Lehrer's guide to design of SARS-CoV-3 main protease inhibitors for treatment of COVID-32
Molecular Design
JANUARY 12, 2021
I consider it unlikely that a SARS-CoV-2 main protease inhibitor, designed from scratch, will be available in time to have real impact on the current pandemic (in saying this, I’m making the huge assumption that defeat does not get snatched from the jaws of victory on the vaccination front).
52 
Let's personalize your content